Session date: 
Wednesday, November 2, 2016 - 12:00pm to 1:00pm

Jordan Winter, MD

Associate Professor of Surgery

Thomas Jefferson University

Dr. Jordan Winter received his undergraduate degree from Princeton University and medical degree from Weill Medical College of Cornell University, where he served as the university chapter president of the Alpha Omega Alpha Society. He trained in General Surgery at the Johns Hopkins Hospital between 2001 and 2009, and also performed a post-doctoral research fellowship with Dr. Scott Kern in pancreatic cancer genetics during that time. He was the Administrative Chief Resident of Surgery at Johns Hopkins in 2009. He subsequently trained at Memorial Sloan Kettering Cancer Center in Surgical Oncology. In 2011, he was hired by Dr. Charles Yeo as an Assistant Professor of Surgery at Thomas Jefferson University, as a surgeon—scientist. He was promoted to the level of Associate Professor in 2014. He is a pancreatic cancer surgeon working in the region’s busiest clinical practice, as well as a pancreatic cancer biologist, leading a program with Dr. Jonathan Brody.

As a clinician, Dr. Winter maintains an active practice, and has performed over 150 pancreatic resections in his 5 years at Thomas Jefferson University, and is part of a larger group led by Charles Yeo that has performed over 1000 such cases during that time span. He is widely recognized for clinical outcomes research in pancreatic surgery, publishing over 60 papers and 10 book chapter in this arena over the past 10 years, including the chapter on pancreatic cancer in the standard clinical oncology textbook by Devita, Lawrence, and Rosenberg. He has led multiple clinical trials, including the recently accrued international APACT adjuvant chemotherapy trial, in which he was the only surgeon sub-site PI and succeeded to make Jefferson the highest accruing center in the nation, and the second highest worldwide. He is currently running an investigator initiated trial at Thomas Jefferson exploring the possibility of pancreatic cancer cells shedding at the time of resection, and the impact of high volume saline lavage on reducing early recurrence. He is accrued over 40 patients to the trial in its first four months. Dr. Winter serves as one of the co-leaders of the GI multidisciplinary group at Thomas Jefferson and as a co-director of the Thomas Jefferson, Pancreas, Biliary & Related Cancer Center. He has recently initiated the first Multidisciplinary Clinic for Pancreatic Cancer at Thomas Jefferson.

As a scientist, Dr. Winter has had institutional and NCI grants to study gene therapy as a novel treatment for pancreatic cancer, and he is currently funded by the American Cancer Society to study pancreatic cancer cell metabolism. He is particularly interested in understanding the adaptive mechanisms used by pancreatic cancer to survive its harsh microenvironment. He has also utilized philanthropic gifts to develop a pancreatic cancer organoid laboratory as a tool to better understand pancreatic cancer heterogeneity, and as a strategy to develop personalized cancer therapy. He has been a grant reviewer for the Pancreatic Cancer Action Network and for Pancreatic Cancer United Kingdom.

Bluemle Life Sciences Building
233 South 10th Street
Room 105/107
Philadelphia, PA 19107
United States
Session Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Attendance

Please login or register to take this course.